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Abstract
Background and Objectives: Several trials have generated conflicting results about the results of high-dose chemotherapy
followed by autologous stem cell transplantation (HDCT) for primary breast cancer. This meta-analysis summarizes the
available evidence from all suitable studies.
Design and Methods: Prospective, randomized trials with HDCT as a first-line therapy for primary breast cancer were
included in this meta-analysis. The primary outcome of interest for our analysis was survival (disease-free survival and overall
survival); secondary endpoints included treatment-related mortality (TRM) and second (non-breast) cancers. We used a
median age of 47, a PR positive rate of 50% and a premenopausal rate of 70% as cutoff values to complete the subgroup
analyses, which were pre-planned according to the prepared protocol.
Results: Fourteen trials with 5747 patients were eligible for the meta-analysis. Compared with non-HDCT, non-significant
second (non-breast) cancers (RR=1.28; 95% CI=0.82–1.98) and higher TRM (RR=3.42; 95% CI=1.32–8.86) were associated
with HDCT for primary breast cancer. A significant DFS benefit of HDCT was documented (HR=0.89; 95% CI=0.79–0.99). No
difference in OS (overall survival) was found when the studies were pooled (HR=0.91; 95% CI=0.82–1.00, p=0.062). In
subgroup analysis, age and hormone receptor status had a significant interaction with prolonged DFS and OS.
Conclusions: HDCT has a benefit on DFS and OS compared to SDC in some special patients with high-risk primary breast
cancer.
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Introduction
In 2010, breast cancer was ranked first in cancer incidence
among women in US, with an estimated 207,090 cases. For
cancer-related mortality, breast cancer was ranked second among
women, with an estimated 39,840 deaths [1]. Patients with stage
III breast cancer or patients with stage II breast cancer and
multiple positive axillary lymph nodes have an approximately 80%
relapse rate at 5 years if treated only with locoregional therapy [2–
4]. One of the strategies to improve the outcome for high- risk
patients was to increase the dose of chemotherapy to enhance its
cytotoxicity. The technique of high-dose chemotherapy followed
by autologous stem cell transplantation (HDCT) has been
considered an exciting development because, by addressing the
problem of bone-marrow toxicity, it permits the administration of
doses many times higher than could otherwise be considered and
thus results in the death of more tumor cells. Therefore, most
research on breast cancer management focuses on improving
breast cancer outcomes in this area.
A prospective randomized clinical trial is the accepted standard
for comparing different treatments, such as different treatments for
primary breast cancer. Many randomized trials performed by
several institutions across the world have addressed conflicting
results regarding the benefit of HDCT for primary breast cancer. A
large meta-analysis of 13 randomized trials including 5,064 women,
showed a significant benefit in event-free survival for the HDCT
group, and overall survival rates were not significantly different at
anystage offollow-up[5].However, individualpatientdatafrom 15
known randomized trials including 6,210 patients showed a modest
improvement in OS (HR 0.89; 95% CI 0.81–0.98; P=0.016) for
the HDCT group compared with standard dose chemotherapy
(SDC) [6]. It became unclear whether HDCT results in a survival
benefit compared with SDC. To arrive at comprehensive estimates
of the survival benefit from the totality of the data available, we
performed a meta-analysis of all relevant randomized trials that
compared HDCT with SDC in patients with primary breast cancer
in order to search for the proper subgroup of patients who will
benefit from this kind of treatment. It was performed in accordance
with the Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) guidelines [7]. The protocol for this trial
and supporting PRISMA checklist are available as supporting
information; see Checklist S1 and Protocol S1.
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Search strategy
The Cochrane Controlled Trials Register, MEDLINE and
EMBASE were searched until March 2010. The publication type
term was Randomized Controlled Trial. No other restrictions were
applied. Additionally, reference lists of all identified trials and of
comprehensive reviews in the field were screened. The volumes of
abstracts of the annual meetings of the American Society of
Hematology (ASH), the European Haematology Association
(EHA), and the American Society of Oncology (ASCO) were
screened from 1995 to 2010.
Inclusion and exclusion criteria
For inclusion, the trials had to be prospective and randomized
with standard conventional chemotherapy in one arm compared
with high-dose chemotherapy followed by autologous stem cell
transplantation in the other arm as first-line therapy of patients
with primary breast cancer. Trials not fulfilling the inclusion
criteria were excluded.
Extraction process
A structured form was used to extract relevant data from the
trials. Extraction was performed independently by two reviewers.
Disagreements were resolved by consensus. Reviewers were not
blinded to availability, as abstracts were obtained personally.
Outcome and definition
The primary outcome of interest for our analysis was survival
(disease-free survival and overall survival); secondary endpoints
included treatment-related mortality (TRM) and second (non-
breast) cancers. The above information was extracted from each
study. We did not define any minimum number of patients to
include a study in our meta-analysis.
Statistical analysis
To estimate the treatment effects, outcomes were calculated as
either relative risks (RRs) or hazard ratios (HRs), with their
respective 95% confidence intervals (CIs) (a benefit of HDCT
would be represented by an HR or RR,1). Survival outcome data
were synthesized using the time-to-event hazard ratio as the effect
measure. When HRs were not given in a paper, data were
extracted from the respective Kaplan-Meier curves to calculate
HRs [8]. Heterogeneity was checked by a Q-test. A p value of
more than 0.10 for the Q-test indicates a lack of heterogeneity
across trials. Considering the inherited heterogeneity between
these studies, we assumed the presence of statistical heterogeneity
and decided to use a random effects model before pooling the
data. Evidence of publication bias was determined using the
methods of Egger et al. and Begg et al. Moreover, contour-
enhanced funnel plotting was performed to aid the interpretation
of the funnel plot [9]. Tests of interaction across the subgroups
were performed to assess whether the benefit of HDCT varied
significantly among patients of different conditions. Review
Manager (Version 5.0 for Windows) and STATA 10.0 were used
for the statistical analysis.
Subgroup analysis
Subgroup analysis was conducted in an effort to determine
whether modification of the inclusion criteria of this meta-analysis
affected the final results. The median patient age was 46 years,
hormone receptor (PR) status was positive in 46.8% of patients,
and 68.9% of patients were premenopausal in the overall
population [6]. We performed the subgroup analysis, which were
pre-planned according to the prepared protocol for this meta-
analysis, by limiting the meta-analysis to studies using the
following criteria (Table 1): (a) Median age ,47 in each group;
(b) PR positive (positive if either estrogen or progesterone receptor
was positive) rate .50% in each group; and (c) Premenopausal
rate .70% in each group.
Results
The process of identification and selection of the relevant
randomized controlled trials (RCT) according to the PRISMA
statement is depicted in Figure 1. Since the late 1990s, a total of 15
randomized trials in high-risk primary breast cancer of HDCT
have been described [10–24]. Fourteen of these trials were used in
our analysis [10–23] with six of them updated after longer follow-
up [25–30], including 5747 patients (2897 patients treated with
HDT/ASCT, and 2850 control patients). Gianni et al.’s study [24]
was excluded from this analysis because of an insufficient amount
of data. All included trials are available as fully published papers.
Table 2 shows the characteristics of the trials included. Study
quality is shown in Table 3. We also did not explicitly score the
methodological quality of the included trials, because the value of
doing so is controversial [31].
Meta-analysis
The overall results of this analysis are shown in Figure 2. TRM
was reported in 10 studies [10,11,13–17,19,21,23]. Patients
randomly assigned to HDCT had a statistically significantly
greater risk of death than patients randomly assigned to receive
chemotherapy only. More deaths were found among the patients
assigned to HDCT than among the patients who received
chemotherapy only (RR=3.42; 95% CI=1.32–8.86). Eleven
studies reported the risk of second (non-breast) cancers [11–16,18–
22]. The risk of second (non-breast) cancers was not significantly
different in the group assigned to HDCT from the group assigned
to chemotherapy only (RR=1.28; 95% CI=0.82–1.98). DFS data
were available for 14 studies [10–23]. DFS was better with HDCT
than with chemotherapy only (HR=0.89; 95% CI=0.79–0.99).
Of the 14 studies for which overall survival data were available
[10–23], the difference in overall survival was not statistically
significant [(HR=0.91; 95% CI=0.82–1.00), p=0.062].
Subgroup analysis
Protocol as described in the methods section, the studies were
summarized in subgroups according to a cut off value regarding
certain characteristics. The subgroup analysis was performed
according to a variety of criteria, and the outcome is shown in
Table 4.
Publication bias
Begg’s funnel plot and Egger’s test were performed to assess the
publication bias in the literature. All studies investigating DFS
yielded a Begg’s test score of p=0.547 and an Egger’s test score of
p=0.609. According to the contour-enhanced funnel plot
(Figure 3), publication bias was not found in any study. Similar
results were found for OS (p=0.622 and 0.540). The contour-
enhanced funnel plot suggests no presence of publication bias for
DFS and OS.
Discussion
This meta-analysis combines the results from fourteen
methodologically satisfactory trials that prospectively enrolled
HDCT for Primary Breast Cancer
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breast cancer to therapy with either HDCT or conventional
chemotherapy. Our pooled results suggests that HDCT is
associated with a modest advantage in DFS ((HR=0.89;
95% CI=0.79–0.99) but not in OS (HR=0.91; 95%
CI=0.82–1.00, p=0.062). However, it was found that age and
hormone receptor status had a significant interaction with
prolonged OS.
Retrospective research had suggested that HDCT in high-risk
primary breast cancer demonstrated significant favorable out-
comes compared with historical data, but a prospective random-
ized clinical trial is the accepted standard for comparing different
treatments such as HDCT for high-risk primary breast cancer. In
fact, the results of prospectively randomized clinical trials were
conflicting. Finally, other trials have shown nonsignificant trends
in favor of HDCT. Only in the WSG trial, which employed
tandem HDCT, did the EFS advantage translate into an OS
benefit [22]. An important factor that might account for the
superiority of HDCT in the WSG trial is the double autologous
stem-cell transplantation. High-dose therapy with tandem autol-
ogous stem-cell rescue is effective for treating high-risk neuroblas-
toma [32] and multiple myeloma [33] with encouraging long-term
survival. If we excluded the WSG trial [22] from our meta-
analysis, the final conclusion that age and hormone receptor status
had a significant interaction with prolonged OS would not have
changed (data not shown).
In an effort to shed some light on the impact of HDCT as a first-
line treatment for high-risk primary breast cancer, the data were
pooled from available published trials for meta-analysis. However,
two previous meta-analyses [5,6] provided different evidence of
the impact of HDCT on high-risk primary breast cancer outcome.
The combined HRs, which are the preferred summary statistics
for reporting time-to-event data [8], were not used in the
previously published meta-analyses [5]. The most widely recom-
mended approach for summarizing the effect of treatment from
time-to-event data in clinical trials is to use a hazard ratio. The
best statistic to use is the hazard ratio (HR) in Meta-analyses of
published time-to-event outcomes. HRs given in trial reports can
be used directly, or if sufficient summary statistical information or
Kaplan-Meier curves are presented, then HRs can be estimated
indirectly [8].
Another meta-analysis was based on individual patient data
(IPD) for the OS. For time-to-event outcomes, the gold standard
approach is to obtain IPD from each included study. IPD should
overcome problems of within-study selective reporting [34] and
should allow a more complete analysis including the potential to
investigate treatment–covariate interactions [35]. IPD meta-
analyses are difficult to perform because of challenges in
collecting the patient-level data. This analysis was displayed as
an abstract, and no details were shown. We could get the data of
median age, PR status and menopausal (MP) status of the whole
population [6], so we used a median age of 47, a PR positive rate
of 50% and a premenopausal rate of 70% as cutoff values to
complete the subgroup analyses. Therapeutic strategies are
generally based on the endocrine responsiveness and the
estimated risk of relapse defined by tumor size, axillary lymph
node involvement, histologic and nuclear grade, lymphatic and/
or vascular invasion, HER2/neu-overexpression and age [36].
Our pooled results suggest that HDCT is associated with a
modest advantage in DFS; however, the EFS advantage did not
translate into an OS benefit. When we subgrouped the studies
according to age and hormone receptor status, we found a
prolonged OS while performing HDCT in high-risk primary
breast cancer. The analyses of the Dutch [12] and WSG [22]
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negative and triple-negative (ER/PR/HER2-negative) status
[37]. The hypothesis-generating observations suggest that this
breast cancer category presents increased sensitivity to dose
intensification of alkylating agents and should remain the subject
of clinical HDCT studies [37].
Treatment-related-mortality (TRM) may account for our
finding that improved DFS did not translate into improved OS.
Patients who received HDCT had a greater risk of dying during
remission than patients who received non-myeloablative chemo-
therapy, primarily because of the toxicity associated with the
regimen resulting in patients’ protracted pancytopenia, which
results in a prolonged risk of infection or bleeding. Although the
DFS may be prolonged by HDCT, the benefit was offset in part by
treatment-related deaths. Two studies reported highly significant
TRM during HDCT [11,13], which was higher than HDCT in
other studies. A considerable reduction in TRM would be needed
to demonstrate a survival benefit from HDCT. Women 50 years
and older appeared to have a higher risk of TRM than younger
women if randomly assigned to HDCT [11]. Young age will result
in a reduced TRM.
Heterogeneity is a potential problem when interpreting the
results of a meta-analysis. However, no evidence for statistically
significant heterogeneity was found in any of the models used. This
result indicates that using an overall estimation of the value of
HDCT may be appropriate. To eliminate heterogeneity, we
divided the 14 studies into subgroups as far as possible;
subsequently, heterogeneity decreased for subgroups of age and
hormone receptor status, which revealed that most of the studies
could not be grouped helpfully according to age and hormone
receptor status.
Quality assessment was based on the reporting of the study
methods and results, namely: randomisation, allocation conceal-
ment, intention to treat, defined inclusion and exclusion criteria,
extent of follow-up described clearly, balanced prognosis. Ad hoc
scores may lack demonstrated validity, and the results may not be
associated with quality [38]. Overall, these studies included in the
analysis were considered of good quality, typically prospective
multicenter trials that reported outcomes analyzed as ITT; were
performed at the national level; and were published in peer-
reviewed journals.
From our analysis, age and hormone receptor status seem to
have a significant interaction with prolonged OS. However, we
must explicitly state that caution is highly advisable when
interpreting subgroup analyses. These cannot be used for
recommendations on treatment selection for individual patients.
Nevertheless, with appropriate care, they can be used in the
development of new, empirically based research.
Figure 1. Process of identification and selection of the relevant randomized, controlled trials according to the PRISMA statement.
doi:10.1371/journal.pone.0033388.g001
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Study ID
Number of
patients
Enrollment
period
Number of
positive nodes
Median
Follow-Up
(years) Median Age
HDC SDC
IBCSG [10] 344 1995–2000 $5 8.3 46 46
SBG [15] 525 1994–1998 .5–8 5 48 48
ICCG [11] 281 1993–2001 $4 5.6 46 48
MDACC [13] 78 1990–1997 $10 or $4 after
chemotherapy
12 45 46
ACCOG [5] 605 1995–1999 $4 6 45 46
SWOG [16] 536 1996–2001 $45 . 8N R
WSG [17] 403 1995–2002 $10 4 48 48
CALGB [6] 785 1991–1998 $10 5.1 44 44
PEGASE 01 [18] 314 1994–1998 $4 2.75 46 46
NWAST [14] 885 1993–1999 $4 7 46 45
Dutch pilot [7] 81 1991–1995 Axillary level III
involvement
6.9 45 48
ECOG [8] 511 1991–1998 $10 6.1 45 43
JCOG [12] 97 1993–1999 $10 5.25 46 47
GABG [9] 302 1993–2000 $10 6.1 NR
ER positive PR positive Premenopausal HDC regimen SDC regimen Included in analysis
HDC SDC HDC SDC HDC SDC
46% 41% NR 67% 67% EC63 A/EC64,
CMF63
TRM, SC, EFS, OS
49.6%
(HRS)
54.2%
(HRS)
NR NR FEC63/4,
CTCb
FEC69 TRM, SC, EFS, OS
64% 74% 46% 56% 68% 72% FEC63,
CTCb
FEC65 TRM, SC, EFS, OS
51% 49% NR NR CAF68,
CEP62
CAF68 TRM, SC, EFS, OS
28% 35% NR NR A64, CT A64
CMF68
TRM, SC, EFS, OS
71%
(HRS)
61%
(HRS)
NR 72% 64% CA64, CPCa/T CAP63 TRM, SC, EFS, OS
59% 64% 61% 63% 51% 50% EC62,
CET62
EC64,
CMF63
TRM, SC, EFS, OS
69%
(HRS)
79%
(HRS)
NR 70% 69% CAF64,
CPCa
CAF64,
CPCa
TRM, SC, EFS, OS
69% 69% NR 68% 68% FEC64
CMMp
FEC64 TRM, SC, EFS, OS
65% 65% 53% 54% 83% 83% FEC64,
CPT
FEC65 TRM, SC, EFS, OS
17% 15% 12% 7.5% 76% 84% FEC64,
CP
FEC64 TRM, SC, EFS, OS
61% 59% 62% 57% 72% 72% CAF66,
CT
CAF66 TRM, SC, EFS, OS
51% 60% 45% 52% 78% 71% CAF66,
CT
CAF66 TRM, SC, EFS, OS
61% 60% 58% 68% 55% 62% EC64,
CMT
EC64,
CMF64
TRM, SC, EFS, OS
ECOG, Eastern Collaborative Oncology group; GABG, German Autologous Bone Marrow Transplant group; IBCSG, International Breast Cancer Study group; ICCG,
International Collaborative Cancer group; JCOG, Japan Clinical Oncology group; MDACC, MD Anderson Cancer Center; NWAST, Netherlands Working Partyo n
Autologous Transplantation in Solid Tumors; SBG, Scandinavian Breast group; SWOG, South Western Oncology group; WSG, West German Study group; EC: epirubicin,
cyclophosphamide; AC: doxorubicin, cyclophosphamide; CMF: cyclophosphamide, methotrexate, fluorouracil; FEC: fluorouracil, epirubicin, cyclophosphamide; CTCb:
cyclophosphamide, thiotepa, carboplatin; CAF: cyclophosphamide, doxorubicin, fluorouracil; CEP: cyclophosphamide, etoposide, cisplatin; A: doxorubicin; CT:
cyclophosphamide, thiotepa; CMF: cyclophosphamide, methotrexate, fluorouracil; CMT: cyclophosphamide, mitoxantrone, thiotepa; CAP: cyclophosphamide,
doxorubicin, paclitaxel; CPCa/T: cyclophosphamide, cisplatin, carmustine/thiotepa; CP: cyclophosphamide, cisplatin; CET: cyclophosphamide, epirubicin, thiotepa;
CMMp: cyclophosphamide, mitoxantrone, melphalan; HRS: hormone receptor status.
doi:10.1371/journal.pone.0033388.t002
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Study ID
Secure
randomisation
Concealed
allocation
Intention
to treat
Inclusion and exclusion
criteria defined
Extent of follow-up
described clearly Balanced prognosis
IBCSG Yes Yes Yes Yes Yes Yes
SBG Yes Yes Yes Yes Not
stated
Yes
ICCG Yes Yes Yes Yes Not
stated
Yes
MDACC Yes Yes Yes Yes Not
stated
Yes
ACCOG Yes Yes Yes Exclusion
criteria not
stated
Yes Yes
SWOG Method not
stated
Not
stated
Not
stated
Yes Not
stated
Yes
WSG Yes Yes Yes Yes Not
stated
Yes
CALGB Method not
stated
Not
stated
Yes Yes Not
stated
Yes
PEGASE 01 Method not
stated
Not
stated
Yes Not
stated
Not
stated
Yes
NWAST Yes Yes Yes Yes Not
stated
Yes
Dutch pilot Yes Yes Yes Exclusion
criteria not
stated
Yes Yes
ECOG Method not
stated
Not
stated
Yes Yes Not
stated
Yes
JCOG Yes Yes Yes Yes Yes Yes
GABG Yes Yes Yes Yes Not
stated
Control arm had less women with
,16+ve nodes, small tumours
doi:10.1371/journal.pone.0033388.t003
Figure 2. Forest plot of the RR/HR. The size of the squares reflects each study’s relative weight and the diamond (e) represents the aggregate
RR/HR and 95% CI. (A) Second cancers; (B) Treatment-related mortality; (C) Disease-free survival; (D) Overall survival.
doi:10.1371/journal.pone.0033388.g002
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results of our analysis. First, our results were based on unadjusted
estimates, while a more precise analysis could be conducted if
individual data were available, which would allow for adjustment
by other co-variates. Second, this analysis does not use primary
patient data, but rather relies on information available in prior
publications. Because of the lack of original data, one RCT was
excluded because no information on HR was available [24].
Third, only published studies were included in this meta-analysis.
Nonsignificant or negative findings may be unpublished. Farquhar
et al. [5] reported 6 ongoing RCT of HDCT in primary breast
cancer; however, we only found two such articles. In addition, our
analyses did not clarify whether double unit grafts would influence
the outcome of HDCT in primary breast cancer.
In conclusion, HDCT has a benefit on DFS and OS compared
to SDC in some special patients with high-risk primary breast
cancer. Because of the limitations that we mentioned above, our
results may not be used as a guideline for primary breast cancer
treatment. Further study is needed to determine whether specific
subgroups of patients, such as those who are HER2-negative or
triple-negative, also benefit from HDCT. Alternatively, these
questions could be addressed by combining individual patient data
from the completed trials, but such an endeavor would require a
large investment of resources as well as multinational cooperation.
Table 4. Subgroup analysis according to patient characteristics.
patient
characteristics Second Cancer (RR) TRM(RR) EFS OS
RR
(95%CI) H
RR
(95%CI) H
HR
(95%CI) H
HR
(95%CI) H
Q P Q P Q P Q P
All 1.28
(0.82–1.98)
9.95 0.44 3.50
(1.33–9.16)
12.92 0.11 0.89
(0.79–0.99)
28.59 0.007 0.91
(0.82–1.00)
23.07 0.041
Median age ,47 in
each group
+ 1.47
(0.90–2.40)
2.08 0.72 5.91
(1.60–21.89)
8.56 0.13 0.85
(0.75–0.96)
9.16 0.165 0.88
(0.80–0.97)
4.57 0.601
2 0.88
(0.11–7.10)
6.00 0.11 1.46
(0.24–8.86)
NA NA 0.89
(0.66–1.20)
14.64 0.006 0.89
(0.66–1.20)
14.56 0.006
PR positive rate .50%
in each group
+ 1.26(0.79–2.00) 2.82 0.83 3.89(1.26–12.05) 10.52 0.1 0.82
(0.73–0.93)
13.69 0.090 0.85
(0.77,0.93)
10.78 0.292
2 1.36
(0.15–12.43)
7.65 0.05 2.62
(0.23–29.21)
1.96 0.16 1.03
(0.83–1.26)
7.83 0.098 1.11
(0.95–1.29)
2.81 0.422
Premenopausal rate
.70% in each group
+ 1.36
(0.84–2.21)
1.86 0.76 11.88
(2.13–66.16)
3.27 0.20 0.89
(0.79–1.01)
5.49 0.359 0.89
(0.79–1.01)
5.49 0.359
2 1.32
(0.38–4.64)
2.69 0.44 1.27
(0.45–3.61)
0.4 0.94 0.75
(0.65–0.86)
4.78 0.311 0.80
(0.71–1.37)
4.21 0.378
NA: not applicable.
doi:10.1371/journal.pone.0033388.t004
Figure 3. Contour-enhanced funnel plot for publication bias test. (A) Disease-free survival; (B) Overall survival.
doi:10.1371/journal.pone.0033388.g003
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